ICON (ICLR) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed ICON (ICLR) over the past year, gaining 166.3% versus a loss of 11.8%. Over five years, ICLR leads with a -40.2% price change compared with -53.3% for OABI. ICON is the larger company by market cap ($12.67 billion vs $696.4 million), about 18.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICLR | OABI |
|---|---|---|
| Share price | $164.17 | $4.79 |
| Market cap | $12.67B | $696.42M |
| 1-day change | -0.20% | +2.79% |
| YTD return | -9.72% | +151.89% |
| 1-year return | -11.79% | +166.29% |
| 5-year return | -40.19% | -53.26% |
| P/E ratio (TTM) | 172.81 | — |
| Forward P/E | 13.92 | — |
| EPS (TTM) | $0.95 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.25B | — |
| Revenue growth (YoY) | +0.76% | — |
| Net income (latest FY) | $229.34M | — |
| Gross margin | 26.37% | — |
| Operating margin | 5.37% | — |
| Net margin | 2.78% | — |
| 52-week high | $203.91 | $5.43 |
| 52-week low | $66.57 | $1.30 |
| Distance from 52-week high | -19.49% | -11.79% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +12.33% | +73.90% |
| Average volume | 822.57K | 1.47M |
| Shares outstanding | 77.15M | 145.39M |
| Employees | 40,200 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICON is about 18.2 times larger than OmniAb by market value ($12.67B vs $696.42M).
- OABI has outperformed ICLR by 178.1 percentage points over the past year.
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,200 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
ICLR vs OABI FAQ
Which is bigger, ICON or OmniAb?
ICON (ICLR) is larger, with a market capitalization of $12.67B compared with $696.42M for OmniAb (OABI).
Which stock has performed better over the past year, ICLR or OABI?
OABI returned +166.29% over the past 12 months, compared with -11.79% for ICLR (price return, excluding dividends). Past performance does not predict future results.
Are ICON and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.